Clinical trials: Moderate Asthma
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
A Study of CM310 in Subjects With Moderate to Severe Asthma
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe…
- Trial name
- NCT05186909
- Testing
- CM310
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Keymed Biosciences Co.Ltd
Asthma
Combivent® CFC Metered Dose Inhaler (MDI) in Moderate to Severe Asthma
The purpose of this study is to demonstrate the superior bronchodilator efficacy of inhaled Combivent® CFC MDI vs. Albuterol HFA MDI in moderate to severe asthma patients.
- Trial name
- NCT00096616
- Testing
- Combivent® CFC MDI, Albuterol HFA MDI
- Where
- 27 sites in United States
- Volunteers
- 113 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
- Trial name
- RENEW-Asthma (NCT07219173)
- Testing
- Brenipatide
- Where
- 119 sites in United States, Argentina and 10 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Asthma
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose…
- Trial name
- A006-B3 (NCT02210806)
- Testing
- A006 DPI, Proventil® MDI
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
This study will be an open-label, parallel-group comparison of Mometasone Furoate Dry Powder Inhaler (MF-DPI) 200 mcg once daily in the evening with two puffs vs.
- Trial name
- NCT00442117
- Testing
- mometasone furoate dry powder inhaler, Budesonide DPI
- Volunteers
- 180 people
- Sponsor
- Organon and Co
Asthma
Control of Asthma Patients Symptomatic on Inhaled Corticosteroids
The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.
- Trial name
- NCT00330070
- Testing
- IPL512,602 20 mg once daily
- Where
- 8 sites in United States
- Volunteers
- 200 people
- Sponsor
- Inflazyme Pharmaceuticals Ltd
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04891237
- Testing
- 10,000 MG01 + 10,000 T517, 30,000 MG01 + 10,000 T517
- Where
- 32 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Asthma
Selective β2-AR Antagonism in Asthma
The objectives are to assess the safety, tolerability and effect on the airways of TR4 in patients with mild-to-moderate asthma. The Phase 1 trial is randomised, double-blind, placebo-controlled, and ascending-dose in design.
- Trial name
- NCT07272135
- Testing
- TR4
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Trio Medicines Ltd.
Asthma
First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma
GSK3511294 is a humanized monoclonal antibody antagonist of Interleukin (IL)-5 which is known to block binding of IL-5 to the IL-5 receptor complex, causing a reduction in the circulating population of eosinophils.
- Trial name
- NCT03287310
- Testing
- GSK3511294, Salbutamol/albuterol
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Asthma
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
The objective of this study is to assess the long-term safety and efficacy of FlutiForm HFA pMDI 250/10 mcg bid in adolescents and adults with moderate to severe asthma who have completed the study SKY2028-3-005.
- Trial name
- NCT00747318
- Testing
- SKP FlutiForm HFA pMDI
- Where
- 39 sites in United States, Mexico and 3 more
- Volunteers
- 280 people
- Sponsor
- SkyePharma AG
Asthma
Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate Asthma
This is an open-label, randomized, parallel Group, multicenter study to evaluate the efficacy and safety of budesonide novolizer dry powder inhaler compared with budesonide turbuhaler dry powder inhaler in Chinese mild to…
- Trial name
- NCT01269437
- Testing
- Budesonide dry powder inhaler
- Where
- 11 sites in China
- Volunteers
- 332 people
- Sponsor
- NovaMed Pharmaceuticals Inc.
Asthma
Phase II Study to Evaluate the Efficacy of AMG 317
A Multi-center, Randomized, Placebo, Multi-Dose study to evaluate the efficacy of AMG 317 compared with placebo as measured by change in Asthma Control Questionnaire (ACQ) symptom scores from baseline to week 12.
- Trial name
- NCT00436670
- Testing
- AMG 317 75 mg, AMG 317 150 mg, AMG 317 300 mg
- Volunteers
- 294 people
- Sponsor
- Amgen
Asthma
Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma
This Phase 2 study was to investigate the tolerability of unit dose budesonide (MAP0020) at three doses in pediatric volunteers with a diagnosis and history of mild-to-moderate stable asthma and evaluate the pharmacokinetic…
- Trial name
- NCT00995904
- Testing
- 84ug MAP0020, 42ug MAP0020, 21ug MAP0020
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Asthma
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma
This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma.
- Trial name
- NCT01501942
- Testing
- AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide, Buffered Saline
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AIM Therapeutics Inc.
Asthma
Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.
To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174720
- Testing
- Ciclesonide (XRP1526)
- Where
- 11 sites in United States, Brazil and 9 more
- Volunteers
- 708 people
- Sponsor
- Sanofi
Moderate Asthma
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
This is a Phase 3, multicenter, randomized, parallel-group, open-label, non-inferiority clinical trial designed to evaluate the efficacy and safety of N0783 compared to Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) in the…
- Trial name
- FORASMA (NCT07318350)
- Testing
- N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg)
- Sponsor
- Eurofarma Laboratorios S.A.
Allergic Asthma
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.
- Trial name
- NCT05008965
- Testing
- FB825
- Where
- 13 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Oneness Biotech Co., Ltd.
Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function…
- Trial name
- ATLAS (NCT05097287)
- Testing
- Dupilumab
- Where
- 249 sites in United States, Belgium and 21 more
- Volunteers
- 1,339 people
- Sponsor
- Sanofi
Asthma
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose treatment with MK-1029 in adults with mild to moderate persistent asthma.
- Trial name
- NCT01370317
- Testing
- MK-1029
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 27 people
- Sponsor
- Merck Sharp & Dohme LLC